



General Assembly

January Session, 2001

**Proposed Bill No. 6275**

LCO No. 2587

Referred to Committee on Public Health

Introduced by:

REP. BEALS, 88<sup>th</sup> Dist.  
REP. CARDIN, 53<sup>rd</sup> Dist.  
REP. CARUSO, 126<sup>th</sup> Dist.  
REP. CONWAY, 75<sup>th</sup> Dist.  
REP. DAVIS, 50<sup>th</sup> Dist.  
REP. DEMARINIS, 40<sup>th</sup> Dist.  
REP. DONOVAN, 84<sup>th</sup> Dist.  
REP. FELTMAN, 6<sup>th</sup> Dist.  
REP. FLAHERTY, 8<sup>th</sup> Dist.  
REP. FLEISCHMANN, 18<sup>th</sup> Dist.  
REP. GERRATANA, 23<sup>rd</sup> Dist.  
REP. GERAGOSIAN, 25<sup>th</sup> Dist.  
REP. GODFREY, 110<sup>th</sup> Dist.  
REP. GONZALEZ, 3<sup>rd</sup> Dist.  
REP. HAMM, 34<sup>th</sup> Dist.  
REP. MANTILLA, 4<sup>th</sup> Dist.  
REP. MARTINEZ, 128<sup>th</sup> Dist.  
REP. MCCLUSKEY, 20<sup>th</sup> Dist.

REP. MEGNA, 97<sup>th</sup> Dist.  
REP. MERRILL, 54<sup>th</sup> Dist.  
REP. MURPHY, 81<sup>st</sup> Dist.  
REP. NARDELLO, 89<sup>th</sup> Dist.  
REP. O'ROURKE, 32<sup>nd</sup> Dist.  
REP. ORANGE, 48<sup>th</sup> Dist.  
REP. PAWELKIEWICZ, 49<sup>th</sup> Dist.  
REP. RACZKA, 100<sup>th</sup> Dist.  
REP. REINOSO, 130<sup>th</sup> Dist.  
REP. SAYERS, 60<sup>th</sup> Dist.  
REP. SHARKEY, 103<sup>rd</sup> Dist.  
REP. SPALLONE, 36<sup>th</sup> Dist.  
REP. STAPLES, 96<sup>th</sup> Dist.  
REP. THOMPSON, 13<sup>th</sup> Dist.  
REP. VILLANO, 91<sup>st</sup> Dist.  
REP. WILLIS, 64<sup>th</sup> Dist.  
REP. JANOWSKI, 56<sup>th</sup> Dist.  
REP. MALONE, 47<sup>th</sup> Dist.

**AN ACT CONCERNING FAIR PRICING OF PRESCRIPTION DRUGS.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 That the general statutes be amended to provide that : (1) Similar to
- 2 the Maine Rx Program, the State of Connecticut as a market participant

3 shall serve as a pharmaceutical benefit manager on behalf of residents  
4 who have no prescription drug benefit as a part of a private or public  
5 health insurance program and who enroll in the ConnPACE Part B  
6 program, negotiating pharmaceutical drug discounts and voluntary  
7 rebates which may be used to provide lower prices or reimbursements  
8 to such residents and retail pharmacies; (2) there be established a drug  
9 price fairness review board consisting of members of the legislature,  
10 relevant state agencies, pharmaceutical industry, pharmacists, business  
11 community, health insurance industry, providers, and advocates for  
12 low income and senior citizens; (3) by January 2004, the board shall  
13 determine whether prescription drug prices paid under the  
14 ConnPACE Part B program are reasonably comparable to the lowest  
15 prescription drug prices paid by large purchasers in the state and the  
16 Federal Supply schedule, and determine the impact of the ConnPACE  
17 Part B program on prices charged to businesses, hospitals and other  
18 providers of health care; (4) the board shall review the prices charged  
19 for prescription drugs in Connecticut and other jurisdictions, including  
20 prices under bulk purchase programs and other information and  
21 determine a maximum manufacturer price for each of the drugs  
22 offered for sale in Connecticut; and (5) if the board determines that  
23 such prices are not comparable, no drug manufacturer may sell its  
24 drugs in Connecticut at a price exceeding the maximum established by  
25 the board without sanctions to be determined by the General  
26 Assembly.

***Statement of Purpose:***

To lower the cost of prescription drugs for residents, businesses and the State of Connecticut.